You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CLADRIBINE

Showing 76 - 100 of 172
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Sclerosis Trial in Worldwide (Mavenclad®)

Recruiting
  • Multiple Sclerosis
  • Liverpool, Australia
  • +46 more
Aug 23, 2021

Waldenstrom's Macroglobulinemia Trial in Houston (Bortezomib, Rituximab, Valacyclovir)

Active, not recruiting
Has Results
  • Waldenstrom's Macroglobulinemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 5, 2022

Hairy Cell Leukemia Patients

Not yet recruiting
  • Hairy Cell Leukemia
    • (no location specified)
    May 5, 2023

    Multiple Sclerosis Trial in Montpellier (Magnetic Resonance Imaging, Blood withdrawal, Neuropsychological tests)

    Not yet recruiting
    • Multiple Sclerosis
    • Magnetic Resonance Imaging
    • +2 more
    • Montpellier, France
      Neurology Department, Hopital Gui de Chauliac
    Jul 18, 2023

    Multiple Sclerosis, Radiologically Isolated Syndrome, White Matter Lesions Trial in Nice (eVOG)

    Not yet recruiting
    • Multiple Sclerosis
    • +2 more
    • eVOG
    • Nice, France
      Nice University Hospital
    Mar 17, 2023

    d in the Treatment of Multiple Sclerosis

    Not yet recruiting
    • Multiple Sclerosis
    • Measurement of concentrations of orally-used DMDs
    • +3 more
    • Ostrava, Moravian-Silesian Region, Czechia
    • +1 more
    Dec 5, 2022

    Multiple Sclerosis Trial in Worldwide (Mavenclad®)

    Completed
    • Multiple Sclerosis
    • Linz, Austria
    • +91 more
    Dec 16, 2021

    Hematologic Malignancy Trial in Chengdu (Allogeneic Hematopoietic Stem Cell Transplantation)

    Recruiting
    • Hematologic Malignancy
    • Allogeneic Hematopoietic Stem Cell Transplantation
    • Chengdu, Sichuan, China
      West China Hospital of Sichuan University
    Mar 12, 2022

    Acute Myeloid Leukemia in Children Trial in Saint Louis (CIML NK Cell Infusion, CD3+ T Cell Product Infusion)

    Recruiting
    • Acute Myeloid Leukemia in Children
    • CIML NK Cell Infusion
    • CD3+ T Cell Product Infusion
    • Saint Louis, Missouri
      Washington University School of Medicine
    Oct 26, 2022

    Hairy Cell and Other Leukemias, and to Develop Recombinant

    Recruiting
    • Hairy Cell Leukemia (HCL)
    • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center, 9000 Rockville Pi
      Aug 24, 2022

      Langerhans Cell Histiocytosis Trial in Shanghai (Prednisone+Cytarabine+vincristine,

      Recruiting
      • Langerhans Cell Histiocytosis
      • Shanghai, China
        Shanghai Children's Medical Center
      Jul 23, 2022

      Relapsed/Refractory Acute Myeloid Leukemia Trial in Beijing

      Recruiting
      • Relapsed/Refractory Acute Myeloid Leukemia
      • Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
      • Best-Available Therapy(BAT) Regimen
      • Beijing, Beijing, China
        Chinese PLA General Hospital
      Oct 10, 2023

      RMS Patients on Ofatumumab or Ocrelizumab inReal-World Setting

      Recruiting
      • Relapsing Multiple Sclerosis
      • Ofatumumab
      • Ocrelizumab
      • Dubai, United Arab Emirates
        Novartis Investigative Site
      Aug 8, 2022

      Relapsing Multiple Sclerosis, Clinically Isolated Syndrome Trial in San Francisco (Ocrelizumab)

      Recruiting
      • Relapsing Multiple Sclerosis
      • Clinically Isolated Syndrome
      • San Francisco, California
        University of California San Francisco
      Apr 28, 2022

      AML, Relapse Trial in Berne (Epacadostat, Cladribine, Cytarabine)

      Withdrawn
      • AML
      • Relapse
      • Berne, Switzerland
        Departement of Medical Oncology, University Hospital Berne
      Sep 7, 2018

      Hairy Cell Leukemia, Hairy Cell Leukemia Variant Trial run by the NCI (CD22CART cell infusion)

      Recruiting
      • Hairy Cell Leukemia
      • Hairy Cell Leukemia Variant
      • CD22CART cell infusion
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 25, 2023

      Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute Trial in Canada, United States (Iomab-B, Conventional

      Active, not recruiting
      • Acute Myeloid Leukemia
      • +8 more
      • Gilbert, Arizona
      • +23 more
      Feb 22, 2022

      Multiple Sclerosis Trial in Derby (Homologous booster, Heterologous booster)

      Recruiting
      • Multiple Sclerosis
      • Homologous booster
      • Heterologous booster
      • Derby, Connecticut
        Griffin Hospital
      Jan 23, 2022

      Relapsing Remitting Multiple Sclerosis Trial in Worldwide (Pleneva TM BGC20-0134, Placebo)

      Terminated
      • Relapsing Remitting Multiple Sclerosis
      • Pleneva TM BGC20-0134
      • Placebo
      • Gent, Belgium
      • +34 more
      Jun 2, 2022

      Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Trial in

      Completed
      Has Results
      • Recurrent Acute Leukemia of Ambiguous Lineage
      • +5 more
      • Chemosensitivity Assay
      • +4 more
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Jun 29, 2022

      Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute Trial in Marseille (Fludarabine-Cladribine-Busulfan conditioning

      Unknown status
      • Leukemia, Myeloid, Acute
      • Leukemia, Lymphoblastic, Acute
      • Fludarabine-Cladribine-Busulfan conditioning regimen
      • Marseille, Bouches-du-Rhône, France
        Institut Paoli-Calmettes
      Jun 26, 2018

      Adult Acute Myeloid Leukemia, Adult Myelodysplastic Syndrome Trial in United States (Chemotherapy)

      Completed
      Has Results
      • Adult Acute Myeloid Leukemia
      • Adult Myelodysplastic Syndrome
      • Bozeman, Montana
      • +8 more
      Feb 11, 2021

      Hodgkin Lymphoma, Non-hodgkin Lymphoma Trial (Chidamide, Cladribine, gemcitabine)

      Unknown status
      • Hodgkin Lymphoma
      • Non-hodgkin Lymphoma
      • (no location specified)
      Jul 25, 2018

      Leukemia, Myeloid, Acute Trial (Cytarabine, Venetoclax, CPX-351)

      Not yet recruiting
      • Leukemia, Myeloid, Acute
      • (no location specified)
      Nov 25, 2022

      Lymphocytic Leukemia, Chronic Trial in Belarus, Poland (Cladribine, Cyclophosphamide, Rituximab)

      Completed
      Has Results
      • Lymphocytic Leukemia, Chronic
      • Cladribine
      • +2 more
      • Minsk, Belarus
      • +5 more
      Nov 17, 2017